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Abstract: Topiramate (TPM) is one of the novel antiepileptic drugs and exhibits a wide range 
of mechanisms of action. Efﬁ cacy of TPM has been demonstrated in partial-onset seizures 
and primary generalized seizures in adults and children, as both monotherapy and adjunctive 
therapy. More recently, TPM has been proposed as an add-on treatment for patients with lithium-
resistant bipolar disorder, especially those displaying rapid-cycling and mixed states. This paper 
reviews the multiple mechanisms of action and the tolerability proﬁ le of TPM in the light of its 
therapeutic potential in affective disorders. Studies of TPM in bipolar disorder are evaluated, 
and the efﬁ cacy and tolerability issues as a mood stabilizing agent are discussed.
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Introduction
Topiramate (TPM) is a sulfamate derivative of fructose, structurally unrelated to 
existing anticonvulsants (Perucca 1997; Privitera 1997; Glauser 1999; Reife et al 2000; 
Shank et al 2000). It was marketed for the add-on treatment of patients with drug-
resistance partial epilepsy (Shank et al 1994) and, through the following years, it has 
shown a broad spectrum of efﬁ cacy, which extends to refractory partial and secondary 
generalized seizures (Faught et al 1996; Privitera et al 1996), primary generalized 
tonic/clonic seizures (Biton et al 1999) and tonic/atonic seizures associated with the 
Lennox-Gastaut syndrome (Sachdeo et al 1999; Mikaeloff et al 2003). Preliminary 
data suggest that, in addition to its use in epilepsy, TPM may have therapeutic effects 
in some neuropsychiatric conditions, such as bipolar and schizoaffective disorders, 
bulimia, neuropathic pain syndromes, migraine and cluster headache prophylaxis, and 
essential tremor (Kamin 2002; Spina and Perugi 2004; D’Amico et al 2006). The variety 
of proposed clinical applications of TPM is consistent with the multiple mechanisms of 
action. These mechanisms will be shortly reviewed in the present paper, together with 
the psychotropic effects of TPM therapy in both epileptic and non-epileptic patients.
Mechanisms of action of topiramate
Preclinical studies designed to elucidate the mechanisms of action of TPM have 
revealed a broad spectrum of pharmacological properties (Shank et al 2000; White 
2002).
Blockade of voltage-dependent sodium channels
TPM reduces the frequency of activation of voltage-sensitive sodium channels 
in a state- or use- dependent manner. In electrophysiological studies of cultured 
hippocampal neurons, TPM, at micromolar concentrations, has been found to reduce 
the duration of spontaneous epileptiform bursts of neuronal ﬁ ring and the frequency 
of action potentials elicited by a depolarizing of electrical currents (Coulter et al 
1993; De Lorenzo et al 2000). TPM produces a voltage-sensitive, use-dependent, 
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and time-dependent suppression of sustained repetitive 
ﬁ ring (SRF) in cultured mouse spinal cord and neocortical 
cells (McLean et al 2000). However, the activity of TPM on 
sodium channels differs from that of other antiepileptic drugs 
(AEDs), in which a rapid limitation or complete block of SRF 
occurs. Based on these ﬁ ndings, it has been concluded that 
although TPM appears to exert some of its anticonvulsant 
effects by blocking voltage-sensitive, use-dependent sodium 
channels, it does so by a mechanism that seems to differ 
from that of classic sodium channel blocking AEDs such as 
phenytoin (PHT), carbamazepine (CBZ), and lamotrigine 
(LTG). As such, it has been suggested that sodium channel 
blockade may not be the primary mechanism by which TPM 
exerts its anticonvulsant activity (McLean et al 2000).
Potentiation of γ-aminobutyric 
acid-mediated transmission
TPM enhances the effects of the inhibitory γ-aminobutyric 
acid (GABA)-mediated neurotransmission through an inter-
action with the GABA
A
 receptors, resulting in increased 
brain GABA level. At 10–100 μM concentrations, TPM 
has been found to enhance GABA-stimulated chloride 
inﬂ ux in cultured cerebellar granule cells, and to increase 
the frequency of GABA-mediated activation of GABA
A
 
receptors in cultures of cerebellar and cortical neurons, 
exhibiting a concentration-dependent dynamic (Brown et al 
1993; White et al 1995; White et al 1997). These effects do 
not involve an action on the benzodiazepine-binding site on 
the GABA
A
 receptor and some studies indicate that TPM 
does not interact with GABA binding sites or benzodiaz-
epine binding sites on GABA
A
. The anticonvulsant action 
of TPM may be related to an effect at some unidentiﬁ ed 
binding sites of GABA
A
 receptors that are not modulated 
by the benzodiazepine antagonist ﬂ umazenil (Shank et al 
1994; White et al 2000).
Antagonism of non N-methyl-D-aspartate 
glutamate receptor
TPM is known to inhibit neuronal excitatory pathways 
through a selective action at the α-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA) and kainate 
subtypes of glutamate receptors. Some studies have shown 
that TPM (10–100 μM) blocks kainate-evoked inward cur-
rents in cultured hippocampal neurons, possibly by exert-
ing an antagonistic effect at AMPA receptor sites, which 
would represent a novel site of action for an anticonvulsant 
(Coulter et al 1995; Rosenfeld 1997). In contrast, TPM at 
concentrations up to 200 μM, had virtually no effect on the 
activity of N-methyl-D-aspartate (NMDA) on the NMDA 
subtype of glutamate receptors (Coulter et al 1995). Because 
blocking of kainate-evoked currents is a known mechanism 
of decreasing neuronal excitability, this property of TPM 
may contribute to its anticonvulsant activity (Severt et al 
1995). Subsequent studies demonstrated that TPM exerts a 
biphasic effect on kainate-evoked currents (Gibbs et al 2000), 
as revealed by an initial inhibition of the kainate-evoked 
currents, followed by a delayed additional inhibitory effect. 
The delayed effect was observed after the constant application 
of TPM for more than 10 minutes, and the kainate-induced 
currents did not fully return to the initial level during a 2- to 
4-hour TPM washout period. It has been postulated that the 
delayed effect may be associated with an alteration of the 
phosphorylation state of kainate-activated channels.
Negative modulatory effect on L-type 
calcium channels
TPM reduces the amplitude of high voltage-activated 
calcium currents on some calcium channels subtypes, thus 
reducing neurotransmitter release and inhibiting calcium-
dependent second-messenger systems (Zhang et al 1998). 
This activity has been demonstrated mainly at L-type high-
voltage-activated calcium channels, in rat dentate gyrus 
granule cells (Zhang et al 2000). TPM produces a biphasic 
concentration-response curve, in which a greater reduction 
in L-type calcium currents was seen at 10 μmol/L than at 
50 μmol/L, suggesting a mode of action different from other 
calcium channel blockers. These studies provide further 
evidence of the diverse mechanisms by which TPM appears 
to modulate neuronal excitability and suggest that an inhibi-
tory effect on L-type calcium channels is another potential 
anticonvulsant mechanism.
Inhibition of carbonic anhydrase 
isoenzymes
TPM has been demonstrated to be a weak inhibitor of 
type II and type IV carbonic anhydrase (CA), thus modulat-
ing pH-dependent activation of voltage- and receptor-gated 
ion channels (Langtry et al 1997). TPM, like the minor 
anticonvulsant and CA inhibitor acetazolamide, contains 
a sulfamate moiety that is likely to be responsible for its 
CA-inhibiting properties. However, when compared with 
acetazolamide, TPM is approximately 10–100 times less 
potent as an inhibitor of these isoenzymes (Shank et al 
1994; Dodgson et al 2000). Carbonic anhydrase inhibiting 
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properties are considered not to be relevant to anticonvul-
sant activity; they are thought to be of greater relevance in 
determining some of the adverse effects, such as increased 
risk of nephrolithiasis and metabolic acidosis, as observed 
with acetazolamide (Wasserstein et al 1995). However, 
long-term safety data indicate that a very small percentage 
(approximately 1%–2%) of patients receiving TPM report 
the occurrence of renal stones (Shorvon 1996).
Effects on the phosphorylation state 
of membrane proteins
A proposed unifying mechanism that can possibly account 
for the wide range of pharmacological effects exerted by 
TPM on membrane receptor/channel complexes is the action 
on the phosphorylation state of membrane proteins (Shank 
et al 2000). Emerging evidence suggests that TPM may bind 
to phosphorylation sites within AMPA, kainate, GABA
A
, 
and voltage-activated sodium channels. TPM binds to such 
sites on the receptor proteins only in the dephosphorylated 
state, exerting a possible bifold effect. Therefore, TPM can 
modulate ion conductance through the channel, by an imme-
diate allosteric action and it could exert a delayed effect by 
shifting the channels toward the dephosphorylated state (Van 
Kammen and Shank 2002).
Psychotropic profi le of topiramate 
in patients with epilepsy
In early trials, using relatively high doses and also rapid 
dose titration schedules, TPM caused depressive problems 
in 15%–19% of treated patients, and psychosis in 3% 
(Shorvon 1996; Kellet et al 1999). Psychiatric disorders are 
not uncommon in patients with refractory epilepsy receiving 
conventional drugs and a cause-effect relationship cannot 
be easily established. It has been suggested that depression 
secondary to TPM treatment could be a function of high 
starting dose and rapid titration schedule, especially in 
patients with a psychiatric history (Crawford 1998; Mula 
et al 2003a). Moreover, depression has been described in 
normal volunteers and non-epileptic patients prescribed 
TPM (Martin et al 1999; Klufas et al 2001). TPM is 
characterized by a strong GABAergic activity, and the 
causal relationship between GABAergic properties and 
depressogenic effects of anticonvulsants is well known. 
However, there is no good and simple explanation for this 
relationship, although GABA certainly plays a role in the 
pathogenesis of depression. The classical AED which is 
depressogenic – phenobarbitone – is also a GABA-agonist. 
Among the new AEDs, VGA and TGB, whose central 
mechanism is characterized by a GABAergic effect, have 
been associated with depression in several clinical trials 
(Leppik 1995; Thomas et al 1996). Ketter and colleagues 
(Ketter et al 1999) have tried to explain these peculiar 
psychiatric effects of AEDs by distinguishing two main 
classes of anticonvulsants. The ﬁ rst class comprises drugs 
such as barbiturates, benzodiazepines, VPA, vigabatrin, 
tiagabine, and gabapentin, which are primarily GABAer-
gic and demonstrate sedation, fatigue, cognitive slow-
ing, and weight gain, but also possible anxiolytic and 
antimanic effects. The second class, which includes the 
antiglutamatergic drugs felbamate and LTG, demonstrates 
activation, weight loss, as well as antidepressant and 
anxiogenic effects. In this composite picture, TPM holds 
an intermediate position because of its multiple modes 
of action (Figure 1). It has been postulated that patients 
1-GAB Aergic
sedating, anxiolytic, antimanic
2-Anti-glutamatergic
activating, anxiogenic, antidepressive
Felbamate,
LamotrigineTopiramate
Barbiturates,
Benzodiazepines,
Valproate, Vigabatrin,
Tiagabine, Gabapentin
Figure 1 Main categories of psychotropic profi les of anticonvulsants. Modifi ed from Ketter et al (1999).
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who are primarily sedated may proﬁ t from the group of 
anti-glutamatergic drugs and that patients who are primar-
ily activated beneﬁ t from drugs which have GABAergic 
properties (Schmitz 2002).
However, GABAergic neurotransmission is not 
enough to explain the association between TPM and 
depression. Other GABAergic AEDs, such as TGB, 
seem to be less depressogenic than TPM (Leppik 1995), 
and a recent study has demonstrated that hippocampal 
sclerosis is the main risk factor for the onset of depres-
sive symptoms during therapy with TPM in patients with 
epilepsy, despite the same titration schedule (Mula et al 
2003b). In other words, it is not relevant how rapidly we 
are potentiating the GABAergic transmission, but rather 
the potentiation of an aberrant network such as in patients 
with hippocampal atrophy. Interestingly, abnormalities 
in the hippocampi, especially smaller volumes, have 
been described also in patients with a primary affective 
disorder such as major depression (Bremner et al 2000; 
Frodl et al 2002).
In a recent survey of 431 patients with epilepsy 
treated with TPM, psychiatric adverse events occurred 
in 24% patients and an affective disorder developed in 
10.7% patients (Mula et al 2003a). The prognosis of 
depression was good, with a small percentage of patients 
requiring admission to hospital and psychotropic pre-
scription, and 87% of them recovered completely after 
drug discontinuation or dose reduction. In the same 
study the prevalence of psychosis was 3.7% (including 
postictal psychosis, schizophrenia-like psychosis of 
epilepsy, and other psychotic states), with 93.8% of 
psychotic patients having complete remission after 
drug discontinuation. Aggressive behavior with or 
without irritability was observed in 5.6% of the patients, 
while other behavioral abnormalities, such as agitated 
behavior, anger/hostility, or anxiety, developed in 3.9% 
of patients.
In a population of 75 children with epilepsy taking 
TPM, 14.6% reported personality changes, mainly 
decreased functioning at school, aggressive and violent 
behavior, irritability, restlessness, and agitation, with a 
close temporal relation between the initiation of TPM and 
onset of the abnormalities, and a complete recovery when 
the drug was discontinued or dosage reduced (Gerber et al 
2000). Finally, a few cases of manic episodes in patients 
on TPM without a previous psychiatric history have been 
reported in the literature (Schlatter et al 2001; Jochum 
et al 2002).
Rationale for the use of 
topiramate in affective disorders
The role of antiepileptic drugs 
in affective disorders
Bipolar disorder (BD) is a condition with complex 
symptomatology that requires lifetime therapy in the 
majority of patients and presents many challenges to clini-
cians. The pharmacological treatment of BD has evolved 
over the last few decades. Lithium and its augmentation 
strategies with antidepressants and antipsychotics has long 
been the therapeutic standard for the treatment of bipolar 
illness. Nevertheless, lithium therapy is associated with 
a 20%–40% rate of treatment failures (Dubovsky and 
Buzan 1997; Soares and Gershon 2000). Evidence for 
inadequate prophylactic response to lithium treatment 
in rapid cycling patients is fairly substantial (Post et al 
1996). A poor response to lithium is also found in other 
bipolar subtypes, namely patients with dysphoric mania, 
mixed states, and comorbid medical illness or substance 
abuse (Calabrese et al 1996; Silverstone et al 1996; Swann 
et al 1997; Post et al 1998a). An increasingly common 
alternative or adjunctive therapy to lithium has been the 
use of second-generation mood-stabilizing anticonvul-
sant agents (Post et al 1998b). Several controlled studies 
have shown that valproic acid (VPA), which potentiates 
neuroinhibition by GABA, and CBZ, a sodium channel 
blocker, are effective treatments for acute and dysphoric 
mania (Post et al 1998b; Bowden et al 1994; Dunn et al 
1998; Bowden et al 2000); besides, their effects on animal 
models of amygdala-kindled seizures are speculated to 
contribute to their mode of action in BD (Post and Uhde 
1983; Stoll and Severus 1996). The kindling or sensitiza-
tion model of epilepsy, in which repeated subconvulsive 
stimuli eventually produce full-blown seizures, may be 
one plausible model for BD, given a similar progression 
of affective illness in some patients from minor to major 
episodes and from triggered to spontaneous episodes 
(Post et al 1998b). Patients initially experience mood-
related episodes in response to life events, but eventually 
the neurological and biochemical pathways responsible 
for these episodes are sufficiently reinforced to allow 
the autonomous initiation of further episodes (Post and 
Weiss 2004).
The preclinical data from AEDs suggest that there may 
be some general shared biological mechanisms between 
epilepsy and BD. For instance, the balance between 
inhibitory and excitatory amino acids (Petty 1995; Roettger 
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and Amara 1999), and altered function of cellular cation 
pumps (ie, sodium and calcium channels) have been impli-
cated (El Mallakh and Jaziri 1990) in both epilepsy and 
BD. The similarities shared by epilepsy and BD supported 
several clinical trials of newer AEDs in affective disorders. 
Among the newer anticonvulsant agents, LTG has been 
proven to be effective in bipolar depression (Calabrese 
et al 1999; Ernst and Goldberg 2003) and has recently 
been approved by the US Food and Drug Administration 
for the maintenance therapy of BD (Bowden et al 2003; 
Yatham 2004).
TPM exerts either direct or indirect effects on various 
receptor- and voltage-gated ion channels. In addition to 
epilepsy, the molecular targets of TPM have been associ-
ated with the underlying pathologic features of numerous 
disorders of the central nervous system (CNS), suggesting a 
role for TPM as a putative mood stabilizer. Encouragement 
about the potential for use of TPM in treating BD comes from 
several sources, brieﬂ y summarized as follows.
TPM has shown potent anticonvulsant effects in the 
amygdala-kindled rat (Wauquier and Zhou 1996). A ﬁ rst 
putative mechanism involves the sodium channel-blocking 
activity of TPM; this inhibitory effect on neuronal excitabil-
ity is also shared by VPA, CBZ, and LTG. Augmentation of 
inhibitory neuronal responses to GABA seems to be another 
particularly signiﬁ cant action of TPM. A study has reported 
an increase in brain GABA after administration of TPM 
(3 mg/kg) to 6 healthy individuals (Kuzniecky et al 1998). 
Compared with baseline levels, brain GABA concentrations 
measured using in vivo nuclear magnetic resonance spectros-
copy, increased by 72% and 64% at 3 and 6 hours after TPM 
administration. Investigators have suggested that GABAergic 
neurons may play a role in mood disorders, including both 
major depression and BD. Preliminary evidence for this 
proposition came from a study in which progabide, a GABA 
agonist, was found to have a marked antidepressant effect 
(Bartholini 1985). Patients with BD have been found to have 
decreased plasma levels of GABA during both depressive and 
manic episodes (Petty 1995). Therefore low plasma GABA 
has been suggested to be a trait marker for bipolar illness 
(Petty et al 1993). Glutamate is the predominant excitatory 
neurotransmitter in the brain and, similar to LTG, TPM 
also negatively modulates glutamate transmission, although 
it exerts its antagonist activity at the AMPA/kainate type 
glutamate receptor rather than at the NMDA type receptor. 
A further mechanism that may be pertinent in the use of TPM 
for bipolar illness is that TPM is a calcium channel inhibitor, 
particularly active on L-type channels. Although reports of 
calcium channel antagonists such as verapamil and nimodipine 
are mixed regarding clinical efﬁ cacy in mania, Post et al 
(1998a) suggested calcium channel antagonism as a possible 
mechanism for mood stabilization.
The underlying pathophysiology of BD is not well 
understood, and it is likely that anticonvulsants exert 
their antimanic or mood stabilizing properties through a 
variety of mechanisms (Manji and Lenox 2000; Ketter et al 
2003). Table 1 compares the mechanisms of action and 
psychotropic spectrum of TPM with the older and newer 
AEDs used for the treatment of affective disorders. As TPM 
combines the pharmacological properties of these anticon-
vulsants, and possesses additional mechanisms of action, 
it is a particularly promising candidate for the therapy of 
affective disorders.
Do we need another mood stabilizer?
A substantial proportion of patients with BD are not 
adequately responsive to clinical trials with lithium, CBZ 
and VPA, either alone, in combination, or with addi-
tional augmentation of antidepressants and antipsychotics 
(O’Connell et al 1991; Goldberg et al 1995; Gitlin et al 1995; 
Table 1 Mechanisms of action and psychotropic spectrum of selected old and new anticonvulsants used in affective disorders
Mechanisms of action Psychotropic effi cacy
Blockade of voltage
dependent sodium
channels
Antagonism of
glutamatergic
receptors
(receptor type)
Potentiation of
GABA
transmission
Blockade of
calcium channels
(channel type)
Mania Depression
CBZ + (+) (NMDA) (+) − + +
VPA + (+) (NMDA) + + (T) ++ +
LTG + (+) (NMDA) − + (L,N,P) (+) ++
TPM + + (AMPA/k) + + (L) + (+)
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid; CBZ, carbamazepine; GABA, γ-aminobutyric acid; k, kainate; LTG, lamotrigine; NMDA, 
N-methyl-D-aspartate; TPM, topiramate;  VPA, valproic acid.
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Keck and McElroy 1996; Denicoff et al 1997). Therefore, 
TPM may represent an answer to the great need for the 
development of new and more effective treatments (Post 
and Speer 2002). It has been recognized that atypical forms 
of BD, such as rapid cycling and mixed states, are less 
responsive to lithium and, notably, they often show a better 
response to sodium channel-blocking agents, such as CBZ 
and oxcarbazepine, as compared to standard lithium therapy 
(Grinze and Walden 2002). Although improved response 
rates have resulted from CBZ therapy, many patients will 
nevertheless be nonresponsive or experience breakthrough 
episodes on maintenance therapy. In this respect, the peculiar 
mechanism by which TPM inhibits voltage-sensitive sodium 
channels could provide a rather interesting therapeutic option 
for treatment-resistant rapid cyclers.
Moreover, currently available agents utilized in both the 
acute management and the prophylaxis of BD are associated 
with a number of concerns, including diminished efﬁ cacy 
and the incidence of adverse events in signiﬁ cant subsets of 
individuals. These factors result in poor patient adherence 
with the pharmacological regimens and are often associated 
with serious consequences. One of the most troublesome 
side-effects of lithium and many mood stabilizers is weight 
gain, which has also been consistently observed in patients 
treated with the atypical antipsychotics, including clozapine, 
olanzapine, and risperidone (Allison et al 1999; Ganguli 
1999; Osser et al 1999; Wirshing et al 1999).
Quite interestingly, TPM therapy is associated with 
weight loss in overweight individuals, as shown by controlled 
trials in seizure disorder (Norton et al 1997; Rosenfeld et al 
1997). A few preliminary studies have reported decreased 
appetite or weight loss in patients treated with TPM 
for BD (Gordon and Price 1995; Nemeroff 2003; Woods 
et al 2004).
A chart-review study of hospitalized patients with either 
schizophrenia, schizoaffective disorder, BD, or other psy-
chiatric diagnoses included 36 patients treated with a mean 
TPM dose of 260 mg/day (range 100–400) for a mean dura-
tion of 131 days (Chengappa et al 2002). Sixty-ﬁ ve percent 
of TPM-treated patients experienced weight loss. Mean 
weight loss with TPM was 1.2±6.3 kg (decrease in body 
weight 0.7%±7.2%), and mean reduction in body mass index 
(BMI) was 0.5±2.4 kg/m2; both were statistically signiﬁ cant 
compared with weight gain observed in the patients receiving 
either lithium or VPA. A more recent study by Vieta et al 
(2004) addressed the long-term efﬁ cacy and impact on 
body weight of the combination of olanzapine and TPM 
in 26 bipolar spectrum patients. In addition to experiencing 
improved mood stability, the 13 patients who completed the 
1-year follow-up showed a weight change of −0.5±1.1 kg. 
Therefore, olanzapine plus TPM cotherapy appeared to 
carry some beneﬁ t for controlling weight gain in bipolar 
patients.
Taken together, these data indicate that BD patients 
receiving TPM experience body weight loss and a reduction 
in BMI. Although the mechanism responsible for TPM-
induced weight loss is not well understood, the reduction in 
body weight seem to be a function of the baseline weight, 
the dosage and the duration of TPM treatment. This advan-
tage of TPM possibly decreases the medical risks associated 
with obesity. Moreover, the tendency to decrease appetite 
may facilitate better long-term compliance in BD patients 
who have experienced weight gain on other psychotropic 
medications, including lithium, anticonvulsants, or atypical 
antipsychotics (Birt 2003).
Topiramate as add-on therapy for 
bipolar disorder
Based on this multi-faceted rationale, several open trials were 
undertaken in order to evaluate the overall efﬁ cacy and safety 
of TPM in the management of BD. Table 2 lists the studies 
reviewed in this paper.
Treatment-refractory bipolar disorder
In a retrospective chart review of 58 consecutive patients 
with psychiatric disorders refractory to previous treat-
ments including newer anticonvulsants, Marcotte (1998) 
studied the efﬁ cacy and tolerability of TPM as adjunctive 
therapy. Most patients had a diagnosis of rapid-cycling BD 
characterized by manic, hypomanic, or mixed episodes. 
TPM was added to existing therapy at an initial dose of 
25 mg/day and titrated by 50-mg increments every 7 days 
until improvement occurred or a total dosage of 400 mg 
daily was reached. The mean dose was 200 mg/day, with 
a mean duration of 16 weeks of TPM treatment. Clinical 
Global Impression (CGI)-equivalent scores showed 
marked or moderate improvement in 36 (62%) of 58 
total patients, and among patients with rapid-cycling BD, 
39 (89%) showed marked or moderate improvement. 
Adverse events were minor and predominantly related to 
the gastrointestinal tract (nausea, frequent bowel move-
ments) and CNS (paraesthesias, somnolence, fatigue, 
impaired concentration).
A second open-label, 5-week study by Chengappa et al 
(1999) evaluated the effects of TPM as adjunctive treatment 
in the manic and mixed phases of 20 patients with bipolar 
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Table 2 Published clinical trials of topiramate in affective disorders
Reference Study design Patients (n)
Diagnosis
Mean dose
(range)
Trial 
duration
Primary outcomes
Marcotte (1998) Open-label study 
of add-on TPM 
in refractory BD
58
BD I and II, other
psychiatric disorders
200 mg/day
(25–400)
16 weeks 62% marked or moderate improvement 
based on a CGI equivalent scale
(modifi ed Likert scale)
Chengappa et al 
(1999)
Open-label study 
of add-on TPM 
in refractory BD
20
BD I (18),
schizoaffective
disorder (2)
210 mg/day
(100–300)
5 weeks 60% much or very much improved based 
on 50% reduction in YMRS and CGI-BP
scores
McElroy et al 
(2000)
Open-label study 
of add-on TPM in 
refractory BD
56
BD I and II
245 mg/day
(50–1200)
30 weeks 63% initially manic and 27% initially 
depressed much or very much improved 
based on CGI-BP, YMRS, and IDS scores
Eads and Kramer 
(2000)
Open-label study 
of add-on TPM 
in refractory BD
17
BD I (4),
schizoaffective
disorder (7),
schizophrenia (6)
826 mg/day
(50–1600)
32 weeks 47% signifi cantly improved based on GAF
score
Vieta et al 
(2001)
Open-label study 
of add-on TPM in 
refractory BD
21
BD I and II, manic (9),
hypomanic (3) and
depressed (6) phases
158 mg/day 6 weeks 28% showed decrease 50% in YMRS or
HAM-D scores and decrease by 2 points in 
CGI-BP score
Vieta et al 
(2002)
Open-label study 
of add-on TPM in 
refractory BD
34
BD I (28), BD II (3),
BD NOS (2), and 
schizoaffective
disorder (1)
200 mg/day
(100–400)
24 weeks 59% initially manic and 55% initially 
depressed showed signifi cant reduction in
YMRS, HAM-D, and CGI-BP scores
Likouras et al 
(2004)
Open-label study 
of add-on TPM in 
refractory BD
56
BD I
290 mg/day
(200–400)
52 weeks Frequency of manic and depressive 
episodes signifi cantly decreased from 1.31 
(±0.13) to 0.52 (±0.07)
Kusumakar et al 
(1999)
Open-label study 
of add-on TPM in 
rapid-cycling BD
27
Rapid-cycling women
(BP I=9; BP II=18)
105 mg/day
(100–150)
16 weeks 56% signifi cantly improved based on HAM-
D and YMRS scores
Grunze et al 
(2001)
Open-label study 
of add-on TPM in 
acute mania
11 
BD I – acute mania
170 mg/day
(25–200)
10 days on, 
5 days off, 
10 days on
64% and 73% showed YMRS 50% 
improvement in 1st and 2nd trial, 
respectively
Bozikas et al 
(2002)
Open-label study 
of add-on TPM in 
acute mania
14
Acute mania
310 mg/day
(150–700)
4 weeks 61.5% showed a signifi cant response 
(50% reduction in BRMS score)
Bahk et al (2005) Open-label study 
of add-on TPM in 
acute mania
33
Bipolar mania
220 mg/day 6 weeks Overall signifi cant decrease in YMRS (by 
67.9%) and CGI (by 56.6%) scores
Hussain and 
Chaudhry (1999)
Open-label study 
of add-on TPM in 
bipolar depression
45
BD I (27) and  
II (18) – major
depressive episode
275 mg/day
(100–400)
24 weeks 42% showed complete remission (HAM-D 
scores between 3 and 7) and 27% showed 
partial remission (HAM-D scores between
8 and 12)
McIntyre et al 
(2002)
Open-label study 
of add-on TPM in 
bipolar depression
18
BD I and 
II – depressed 
phase
176 mg/day
(50–300)
8 weeks 56% showed 50% reduction from 
baseline in HAM-D score
Guille and Sachs 
(2002)
Open-label study 
of add-on TPM in 
BD with psychiatric 
comorbidity
14 
BD I and II, with 
comorbid conditions
100 mg/day
(25–300)
1–64 weeks
(22 mean)
64% showed increased level of functioning 
(4- to 15-point improvement in GAF 
score)
Calabrese et al 
(2001)
Open-label study
of TPM as
monotherapy in
acute mania
10 
BD I – acute
mania
313 mg/day
(50–612)
2–28 days
(16 mean)
30% showed 50% decrease in YMRS 
score; 20% showed 25%–49% decrease in 
YMRS score
Abbreviations: BD, bipolar disorder; BRMS, Bech and Rafaelsen Mania Scale; CGI, Clinical Global Impression; CGI-BP, Clinical Global Impression-Bipolar version; 
GAF, Global Assessment of Functioning; HAM-D, Hamilton Depression Rating Scale; IDS, Inventory for Depressive Symptoms; TPM, topiramate; YMRS, Young Mania Rating 
Scale.
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spectrum disorder, refractory to previous mood-stabilizing 
therapies. TPM was initiated at a dosage of 25 mg/day 
and increased to a target dose of 100–300 mg/day by 
increments of 25–50 mg/day. Patients were evaluated 
weekly using the Young Mania Rating Scale (YMRS), 
the Hamilton Depression Rating Scale (HAM-D), and the 
Clinical Global Impression-Bipolar version (CGI-BP). 
Twelve (60%) patients were rated as responders to treat-
ment (50% reduction in YMRS and CGI-BP rating of 
much or very much improved) and 3 (15%) patients were 
minimally improved. Treatment with TPM appeared well 
tolerated. Side-effects in this study, nearly all related to the 
CNS or gastrointestinal tract, were transient and resolved 
spontaneously. All patients showed a progressive decline 
in weight during the 5 weeks of TPM therapy, with a mean 
decrease of 4.7 kg.
Similar ﬁ ndings were obtained by McElroy et al (2000) 
in another open-label, prospective, add-on evaluation of 
TPM in 56 bipolar outpatients who had an inadequate 
response to, or were unable to tolerate, at least one stan-
dard mood stabilizer. TPM therapy was started at a dose 
of 25–50 mg/day and increased by 25–50 mg/day every 
3–14 days to a maximum dosage of 1200 mg/day. Two 
patients discontinued TPM in the ﬁ rst week because of diz-
ziness and hallucinations. The mean treatment duration for 
all 54 patients was 214.2 days, and the mean TPM dosage 
was 244.7 mg/day. Patient response was measured every 2 
weeks for the ﬁ rst 10 weeks and monthly thereafter using 
the CGI-BP, YMRS, and the Inventory for Depressive 
Symptoms (IDS). CGI-BP scores at 10 weeks showed that 
19 (63%) of 30 initially manic patients were much or very 
much improved in their manic symptoms; these patients 
also displayed signiﬁ cant decreases in YMRS and IDS. 
Overall, patients with mania at baseline showed signiﬁ cant 
response to TPM, but depressed and euthymic patients 
showed no signiﬁ cant changes. TPM was generally well 
tolerated, with mild and transient CNS and gastrointes-
tinal-related adverse effects, including reduced appetite, 
cognitive impairment, fatigue, and sedation. Statistically 
signiﬁ cant decreases in both weight and BMI were also 
observed.
Eads and Kramer (2000) have also reported a signiﬁ cant 
improvement in mood and global functioning with TPM in 
17 patients with treatment-refractory mood disorders. TPM 
was added to existing treatment and titrated to a mean dose 
of 826 mg/day (range 50–1600 mg/day). Eight patients 
discontinued TPM due to CNS side-effects, such as sedation, 
confusion, dizziness, fatigue, and impaired concentration. 
All the remaining 9 patients responded to the drug, and 8 of 
them showed an 8- to 20-point improvement of the Global 
Assessment of Functioning (GAF) score.
The effectiveness of TPM as adjunctive therapy in 
treatment-resistant BD has also been reported by Vieta 
et al (2001) in a prospective, multicenter, open-label 
study on 21 BD I and II patients in a manic (n=9), 
hypomanic (n=3) or depressed (n=6) phase. All subjects 
were started on adjunctive therapy with TPM 25 mg/day, 
with 25- to 50-mg increments every 3–7 days to a mean 
dose of 158 mg/day. After 6 weeks of therapy, 6 of 
the 15 patients who completed the study were rated as 
responsive to TPM (50% reduction in the YMRS or 
HAM-D and a decrease of 2 points on the CGI-BP). 
Overall, TPM was well tolerated, with adverse effects 
mostly related to the gastrointestinal tract and CNS. The 
authors concluded that TPM may be useful as a safe 
and effective therapy in the treatment of patients with 
refractory BD.
The same authors (Vieta et al 2002) published the results 
of a further study of TPM as add-on, long-term therapy for 
treatment-resistant bipolar disorder. Thirty-four DSM-IV 
bipolar-spectrum patients received increasing doses of TPM 
(mean dose at endpoint: 202 mg/day) as add-on treatment 
for their manic (n=17), depressive (n=11), hypomanic 
(n=3), or mixed (n=3) symptoms. Twenty-ﬁ ve patients 
completed the 6-month follow-up. The intention-to-treat 
analysis showed a signiﬁ cant reduction in YMRS, HAM-D, 
and CGI-BP scores (p0.0001) in 59% of manic patients 
and 55% of depressed patients, suggesting that TPM may 
be useful in the long-term treatment of bipolar spectrum 
disorders. Overall, the drug was well tolerated, and 10 
patients experienced moderate weight loss during the fol-
low-up period.
In a recent open-label study by Lykouras et al (2004), 
56 patients receiving outpatient treatment for bipolar I dis-
order who had been on mood stabilizers, and had relapsed 
at least once in the past 12 months, were treated with 
TPM in an add-on design for one year. Patients were 
assessed biweekly for the ﬁ rst 3 months and every month 
thereafter. Fifty patients completed the study and reported 
a significant reduction of new manic and depressive 
episodes compared to the past 12 months. The mean 
TPM dosage was 290 mg/day, and the most common 
adverse effects were reduced appetite, fatigue and som-
nolence. This exploratory study suggests that the addition 
of TPM could be a feasible option for the maintenance 
therapy of patients with treatment-refractory bipolar I 
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disorder, thus encouraging further investigations, especially 
with controlled trials, for its long-term effect.
Rapid-cycling bipolar disorder
Kusumakar et al (Kusumakar et al 1999) completed 
an open-label study of TPM as adjunctive therapy for 
rapid-cycling BD. Twenty-seven female patients suf-
fering from rapid-cycling BD type I (n=9) and type II 
(n=18) were given TPM at 25 mg/day, with weekly 
increments of 25 mg/day up to an average maximum 
dosage of 105.2 mg/day. All patients were refractory to 
two or more previous mood stabilizers, including lithium 
and VPA, for at least 12 months, and had experienced 
significant weight gain (20%) from previous treat-
ments. After 16 weeks of therapy, 15 patients exhibited 
clinically signiﬁ cant improvement in mood and achieved 
euthymia. Mood assessment (severity and cycle length) 
was performed by the rating scales HAM-D and YMRS, 
and outcome measures included sleep and weight loss. 
Nine patients (33%) reported a weight loss of at least 5%, 
while 5 patients experienced a reduction of 1%–4%. Main 
reasons for discontinuation of treatment (4 subjects) were 
adverse effects, namely drowsiness, ataxia, confusion, 
and re-emergence of psychosis, all of which occurred on 
or before week 3.
Acute mania
Grunze et al (2001) assessed the antimanic efﬁ cacy of TPM 
as adjunctive treatment for 11 acutely manic patients in an 
on-off-on study design. TPM was given openly after stable 
serum levels of mood stabilizers and/or antipsychotics had 
been achieved, at a starting dose of 25 mg/day, and titrated 
within 1 week to a ﬁ nal dose of 25–200 mg/day, depend-
ing on clinical efﬁ cacy and tolerability. After 10 days of 
therapy, TPM was discontinued, while concomitant medi-
cations remained unchanged. On day 16, TPM was reintro-
duced and titrated to former dosages for another 10 days. 
By day 10, 7 of 11 patients showed a good antimanic 
response with 50% reduction in YMRS score. During 
the “off” period, 7 patients worsened again. At the end 
of the study, after the reintroduction of TPM, all patients 
improved again within a week, with 8 patients display-
ing 50% or greater YMRS score reduction. Two patients 
reported sedation and another patient showed psychotic 
features following a rapid increase in the dose of TPM; 
otherwise TPM was generally well tolerated, without 
measurable effects on the plasma levels of concomitant 
medications.
A clinical trial by Bozikas et al (2002) evaluated 4 weeks 
of treatment with TPM in 14 patients admitted to the hospital 
with acute mania. Nine patients received TPM as mono-
therapy; 5 patients received concomitant therapies includ-
ing zuclopenthixol acetate, VPA, CBZ, and risperidone; 
benzodiazepines were used as needed to manage all patients. 
The mean TPM dose in the study was 310 mg/day (range 
150–700). Patients were assessed every week for 4 weeks 
with the Bech and Rafaelsen Mania Scale (BRMS). Mean 
BRMS scores declined from 26.2 to 11.6 in the fourth week 
(p0.001); a signiﬁ cant decline (p0.001) was observed 
after the ﬁ rst week. Response rate (50% reduction of 
BRMS) was 61.5% (8 out of 13 patients). All patients 
tolerated well TPM. Reduced appetite and weight loss was 
observed in 4 obese (BMI30 kg/m2) patients; however, 
2 patients presented weight gain.
A recent study by Bahk et al (2005) compared the 
effectiveness and tolerability of TPM and VPA in com-
bination with risperidone for the treatment of 74 patients 
who met the DSM-IV criteria for bipolar mania. The 
recommended starting doses were 20 mg/day for TPM 
(with 25–50 mg/day increases every 2–5 days to a mean 
daily dose of 220.6 mg) and 750 mg/day for VPA (with 
250–500 mg/day increases every 2–5 days to a mean 
daily dose of 908.3 mg). From the baseline to the end-
point (week 6), the YMRS and CGI scores were reduced 
by 67.9% and 56.6% in the TPM plus risperidone group 
and by 63.7% and 58.2% in the VPA plus risperidone 
group. Weight and BMI increased significantly by 3.6% 
and 3.3% from the baseline to the endpoint in the VPA 
plus risperidone group, while they decreased by 0.5% and 
0.4%, respectively, with no significant difference in the 
TPM plus risperidone group. No serious adverse events 
were reported in either group. The authors concluded that 
TPM may represent a promising alternative to a weight-
gain liable mood stabilizer, such as VPA, for the treatment 
of acute mania.
Van Kammen and Shank (2002) conducted a prospective, 
double-blind, placebo-controlled, three-week study of TPM 
in hospitalized patients with a DSM-IV based diagnosis 
of bipolar I disorder. All patients entering the study had 
a YMRS score of 20 or greater. They were randomized to 
receive either TPM 512 mg/day (n=33), TPM 256 mg/day 
(n=33) or placebo (n=31). TPM was titrated to target dose 
in 10 days, and the efﬁ cacy of treatment against acute 
mania and mixed episodes was measured by changes in the 
YMRS as well as secondary measures, including the GAF 
scale. Both the interim analysis and the efﬁ cacy analysis 
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after the exclusion of the patients who were taking 
antidepressant prior to study entry showed a signiﬁ cant 
reduction in YMRS scores (p=0.027 and p=0.049, 
respectively) for patients taking TPM 512 mg/day when 
compared with patients taking placebo. This difference 
was not maintained in the intention-to-treat analyses due 
to a higher than expected placebo response. The authors 
suggest several reasons for the increased placebo response 
in mania: manic episodes end spontaneously and are time 
limited; hypomania is likely to respond to environmental 
interventions such as hospitalisation; manic symptoms 
improve when antidepressant treatment is discontinued; 
pseudo-manic patients (eg, patients with perimenstrual 
dysphoric disorder) are included. The authors concluded 
that TPM may have a dose-dependent response in manic 
patients with bipolar I disorder.
Bipolar depression
An open-label trial by Hussain and Chaudhry (1999) 
suggests that TPM may also be useful in the treatment 
of depressive episodes in bipolar patients. Forty-five 
patients with bipolar I disorder (n=27) and bipolar II dis-
order (n=18) suffering from a major depressive episode 
and refractory to previous mood-stabilizing therapy were 
given add-on TPM at a starting dose of 25 mg/day, then 
titrated to a mean dose of 275 mg/day. Of the 31 patients 
who completed the trial, 19 were rated as full responders 
(ﬁ nal HAM-D score between 3 and 7), and 12 patients as 
partial responders (ﬁ nal HAM-D-17 score between 8 and 
12). Responses to TPM were observed within the ﬁ rst 
4 weeks of therapy. TPM was generally well tolerated, 
and the main adverse effects leading to withdrawal were 
dizziness and nausea.
McIntyre et al (2002) compared the efficacy and 
tolerability of TPM and sustained-release bupropion 
added to mood stabilizers in a randomized, single-blind 
study of 36 outpatients with bipolar I or II depression 
(baseline HAM-D-17 scores 16). Each 18-patient treat-
ment group received escalating doses of either TPM (to 
a mean dose of 176 mg/day) or bupropion (250 mg/day) 
for 8 weeks. A significant and comparable reduction in 
depressive symptoms (50% reduction in HAM-D-17 
score between baseline and endpoint) was observed during 
treatment with the two drugs. Medications were generally 
well tolerated, though 6 TPM and 4 bupropion patients 
discontinued due to side-effects. No cases of induction 
of mania were observed. Weight loss was noted in both 
groups (mean weight loss was 5.8 kg for TPM and 1.3 kg 
for bupropion).
Bipolar disorder with psychiatric 
comorbidity
Guille and Sachs (2002) assessed the efficacy and 
tolerability of TPM in 14 patients with treatment-
refractory bipolar disorder as well as comorbid psychi-
atric conditions, including bulimia, anorexia nervosa, 
post-traumatic stress disorder, obsessive compulsive 
disorder, and Tourette’s syndrome. TPM was initiated at 
a dose of either 25 or 50 mg and data were collected for 
a mean duration of 22.4±22.0 weeks; the mean dose at 
endpoint was 100mg/day. Eleven patients remained on 
treatment for longer than 2 weeks. TPM was discontin-
ued in 5 patients due to side-effects (rash, paraesthesias, 
cognitive impairment, and sedation) and in 2 patients due 
to lack of efﬁ cacy after less than 2 weeks. Nine patients 
(64%) experienced an increased level of functioning (4- to 
15-point improvement in GAF score) and 4 experienced 
a decrease in symptom severity of bipolar illness (by 1 
CGI point) during treatment with adjunctive TPM. Eight 
patients (73%) experienced a signiﬁ cant improvement 
in their comorbid conditions as measured by the CGI-I 
(Clinical Global Impression of Improvement). Patients 
with a BMI28 (n=4) experienced a mean weight loss of 
29.7 lb while on TPM. These ﬁ ndings suggest that TPM 
represents a promising agent for the treatment of bipolar 
disorder associated with comorbid psychiatric conditions, 
such as eating disorders and obesity.
Topiramate monotherapy for 
bipolar disorder
Acute mania
Open-label TPM was given as monotherapy for acute mania 
in a small pilot study by Calabrese et al (2001) of 10 patients 
with bipolar disorder type I who were unresponsive to 
lithium and/or VPA. After a 3-day washout period, TPM 
was initiated at 50 mg/day and titrated upward as tolerated 
by 50 mg every 3 days (mean dosage 313 mg/day) for up 
to 28 days. Three patients had a 50% reduction in mania 
scores (as assessed by YMRS); another 2 patients had 
scores that improved by 25%–49%. Moreover, 5 patients 
had increased level of functioning and global impression 
scores (as assessed by CGI-I). Response occurred between 
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200 and 400 mg/day. Treatment was generally well tolerated, 
with paraesthesias as the most common side-effect. Three 
of 4 patients completing 28 days of treatment reported a 
signiﬁ cant weight loss.
What is the role of topiramate in 
bipolar disorder?
The results of preliminary studies show promise for TPM as 
an addition to the agents currently available to treat patients 
with bipolar illness. Clinical data from uncontrolled open-
label studies and patient-reviews involving several hundred 
subjects suggest that TPM is effective in the treatment of 
various presentations of BD, especially in acutely manic 
and rapid cycling patients (Chengappa et al 2001; Maid-
ment 2002; Suppes 2002). In the majority of these studies, 
over 50% of patients who were previous non-responders to 
or intolerant of lithium or other mood stabilizing therapy 
showed an improvement following treatment with TPM, 
according to standard assessment scale scores.
Open-label experience indicates better antimanic than 
antidepressant efﬁ cacy (Yatham et al 2002; Evins 2003), 
since the data for TPM in bipolar depression have shown 
mixed results. Moreover, induction of depression has been 
described as a possible consequence of anticonvulsant therapy 
with TPM among some patients with epilepsy (Ketter et al 
1999; Mula et al 2003a). However, the scarcity of published 
randomized trials limits deﬁ nitive conclusions about the acute 
antidepressant properties of TPM. Similarly, the role of TPM 
in the preventive treatment of BD is not known due to lack 
of data. Although most studies described here had a rela-
tively short duration, overall efﬁ cacy and tolerability results 
support further study on its use for maintenance treatment 
of BD, as an adjunctive agent or possibly as monotherapy. 
Combination therapy of AEDs with lithium and other mood 
stabilizers appears to be more effective than monotherapy 
with these agents in many bipolar patients (Pies 2002). TPM 
is more likely to be prescribed in combination with another 
mood stabilizer for the management of BD. Although com-
bination therapy may increase the risk of toxicity and drug 
interactions, particularly with psychotropic agents (Freeman 
and Stoll 1998), the generally benign side-effect proﬁ le of 
TPM and early clinical ﬁ ndings are good indications that this 
drug may be used safely in combination with other mood 
stabilizers in BD. In particular, the observed anorexic or 
weight loss effect of TPM is noteworthy, since it promotes 
better long-term compliance in patients who have experi-
enced weight gain on other psychotropic agents, including 
lithium, anticonvulsants, or atypical antipsychotics. A clinical 
scenario where this agent may be arguably helpful is among 
obese bipolar subjects where efﬁ cacy combined with weight 
loss is required. Other clinically relevant target populations 
among bipolar patients may include rapid-cycling subjects, 
and subjects whose mood instability is complicated by TPM-
responsive comorbid conditions, such as migraine, neuro-
pathic pain, bulimia, and post-traumatic stress disorder.
Clinical studies of TPM in psychiatric populations report 
a similar tolerability proﬁ le to that observed in epilepsy. The 
most common adverse events are CNS-related and include 
somnolence, fatigue, dizziness, headache, paraesthesias, 
ataxia, diplopia, and nystagmus. Cognitive impairment 
has been associated with TPM therapy: impaired attention 
and concentration, memory problems, confusion, abnormal 
thinking, word-ﬁ nding difﬁ culties, dysnomia/anomia, as 
well as psychomotor slowing, have all been reported in 
both mood disorders and epilepsy (Chengappa et al 2001; 
Tatum et al 2001; Maidment 2002; Suppes 2002; Mula 
et al 2003c). Notably, most side-effects are transient and 
tend to resolve spontaneously or with dosage reduction. 
Moreover, in subjects with epilepsy, CNS adverse effects 
may often be prevented or minimized by a slower titra-
tion rate (25 mg every week), lower doses of TPM, and 
fewer adjunctive therapies, although some of them seem 
to occur in a subgroup of patients with a speciﬁ c biologic 
vulnerability (Rosenfeld et al 1992; Shorvon 1996; Mula 
et al 2003b).
At this time, the majority of the available data on TPM 
in affective disorders are limited by open and naturalistic 
studies which have several methodological shortcom-
ings. These studies were non-randomized and open-label 
in design, involving heterogeneous patient populations 
(such as bipolar I and II, schizoaffective, rapid-cycling 
course), with incomplete information on current or past 
treatment for the illness. In most cases, TPM was used 
as adjunctive therapy in patients inadequately responsive 
to or intolerant of standard mood stabilizers, potentially 
introducing outcome bias. Finally, in the absence of 
head-to-head controlled monotherapy comparisons, it is 
difﬁ cult to compare and contrast efﬁ cacy beneﬁ ts versus 
side-effect risks for TPM and the long-standing bipolar 
treatment agents. Therefore, further studies of TPM are 
warranted, with double-blind placebo-controlled designs 
to provide more deﬁ nite data on the efﬁ cacy and safety of 
this agent as a mood stabilizer for subjects suffering from 
bipolar disorder.
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Conclusions
TPM has a broad spectrum of pharmacological activities, 
facilitating a balance between inhibitory and excitatory neu-
rotransmission and overall decreasing neuronal excitability. 
AEDs such as CBZ and VPA have already shown efﬁ cacy 
as mood stabilizers, and the newer anticonvulsant LTG has 
recently been approved for the maintenance treatment of 
BD type II. However, TPM has several pharmacological 
advantages, including low protein binding, minimal hepatic 
metabolism and mainly unchanged renal excretion, a long 
half-life that permits twice daily dosing, few drug interac-
tions in combination therapy, and no requirement for blood 
level monitoring. Preliminary open-label clinical trials have 
evaluated the efﬁ cacy of TPM, both as an add-on treatment 
and as monotherapy, in various episodes or subtypes of BD, 
including acute mania, depression, rapid-cycling disorder, 
mixed mania, and BD refractory to usual medications. 
Results of these early trials are promising, particularly in 
patients who are acutely manic or rapid cyclers, and those 
who failed to respond to standard mood stabilizing pharma-
cological regimens. In addition to its efﬁ cacy, TPM offers 
a favorable side-effect proﬁ le, which includes decreased 
appetite and weight loss in some patients. This effect, 
especially positive for subjects who have gained weight 
on lithium, other AEDs, or atypical antipsychotics, may 
ultimately contribute enhancing compliance to the mood 
stabilizing treatment. On the whole, TPM is well tolerated 
by both epileptic and bipolar patients, the most commonly 
reported adverse events being minor CNS-related effects, 
including cognitive slowing, which tend to resolve over time 
with dosage reduction.
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